TrialEuropean urology2024

Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 Trial.

Kelly N Fitzgerald et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.